$MGTX
MeiraGTx Holdings plc

2024 Q3 Form 10-Q Financial Statement

#000155837024011788 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $10.91M $282.0K
YoY Change 113.8% -92.03%
Cost Of Revenue $11.99M
YoY Change
Gross Profit -$1.075M
YoY Change
Gross Profit Margin -9.85%
Selling, General & Admin $24.71M $11.26M
YoY Change 146.83% -9.13%
% of Gross Profit
Research & Development $26.24M $34.93M
YoY Change -5.79% 75.22%
% of Gross Profit
Depreciation & Amortization $3.260M $3.222M
YoY Change -6.32% -0.77%
% of Gross Profit
Operating Expenses $50.95M $46.19M
YoY Change 34.56% 42.9%
Operating Profit -$40.04M -$45.91M
YoY Change 22.22% 59.49%
Interest Expense $3.357M $3.254M
YoY Change -0.71% -3.01%
% of Operating Profit
Other Income/Expense, Net -$49.00K -$49.00K
YoY Change 22.5% 4800.0%
Pretax Income -$39.33M -$48.62M
YoY Change -11.22% 64.36%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$39.33M -$48.62M
YoY Change -11.21% 64.36%
Net Earnings / Revenue -360.49% -17241.13%
Basic Earnings Per Share -$0.55 -$0.76
Diluted Earnings Per Share -$0.55 -$0.76
COMMON SHARES
Basic Shares Outstanding 64.90M 64.31M
Diluted Shares Outstanding 71.63M 64.38M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $122.9M $99.97M
YoY Change 93.81% 7.76%
Cash & Equivalents $122.9M $99.97M
Short-Term Investments
Other Short-Term Assets $713.0K $660.0K
YoY Change -5.94% -57.34%
Inventory
Prepaid Expenses $7.029M $4.955M
Receivables $3.279M $1.628M
Other Receivables $5.152M $3.557M
Total Short-Term Assets $139.0M $110.8M
YoY Change 34.3% -22.61%
LONG-TERM ASSETS
Property, Plant & Equipment $112.5M $108.8M
YoY Change 0.59% -4.53%
Goodwill
YoY Change
Intangibles $951.0K $969.0K
YoY Change -16.58% -22.6%
Long-Term Investments $6.766M $6.766M
YoY Change 6.96% 6.96%
Other Assets $1.139M $1.139M
YoY Change -19.85% -22.25%
Total Long-Term Assets $160.4M $155.9M
YoY Change -1.97% -6.73%
TOTAL ASSETS
Total Short-Term Assets $139.0M $110.8M
Total Long-Term Assets $160.4M $155.9M
Total Assets $299.5M $266.7M
YoY Change 12.09% -14.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $29.50M $21.40M
YoY Change 42.03% -24.91%
Accrued Expenses $19.34M $16.93M
YoY Change -31.54% -31.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $59.42M $47.01M
YoY Change -6.45% -34.53%
LONG-TERM LIABILITIES
Long-Term Debt $72.94M $72.67M
YoY Change 1.59% 1.53%
Other Long-Term Liabilities $71.39M $66.94M
YoY Change 79.38% 55.05%
Total Long-Term Liabilities $144.3M $139.6M
YoY Change 29.33% 21.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $59.42M $47.01M
Total Long-Term Liabilities $144.3M $139.6M
Total Liabilities $203.8M $186.6M
YoY Change 16.23% -0.07%
SHAREHOLDERS EQUITY
Retained Earnings -$662.6M -$623.3M
YoY Change 15.36% 17.58%
Common Stock $3.000K $3.000K
YoY Change 50.0% 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $95.74M $80.04M
YoY Change
Total Liabilities & Shareholders Equity $299.5M $266.7M
YoY Change 12.09% -14.06%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$39.33M -$48.62M
YoY Change -11.21% 64.36%
Depreciation, Depletion And Amortization $3.260M $3.222M
YoY Change -6.32% -0.77%
Cash From Operating Activities -$25.02M -$19.46M
YoY Change 2.47% -32.94%
INVESTING ACTIVITIES
Capital Expenditures $730.0K $1.329M
YoY Change -79.49% -73.29%
Acquisitions
YoY Change
Other Investing Activities -$584.0K $0.00
YoY Change
Cash From Investing Activities -$1.314M -$1.329M
YoY Change -63.09% -73.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 49.96M 1.603M
YoY Change -12284.63% -97.23%
NET CHANGE
Cash From Operating Activities -25.02M -19.46M
Cash From Investing Activities -1.314M -1.329M
Cash From Financing Activities 49.96M 1.603M
Net Change In Cash 23.62M -19.18M
YoY Change -183.2% -180.06%
FREE CASH FLOW
Cash From Operating Activities -$25.02M -$19.46M
Capital Expenditures $730.0K $1.329M
Free Cash Flow -$25.75M -$20.79M
YoY Change -7.96% -38.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.15
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64376396
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55349534
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62221145
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52012382
dei Entity Central Index Key
EntityCentralIndexKey
0001735438
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63601015
mgtx Excess Tax Benefit From Share Based Compensation Operating Activities1
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1
0
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64684187
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
mgtx Operating Lease Number New Leases Recognized
OperatingLeaseNumberNewLeasesRecognized
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38520
dei Entity Registrant Name
EntityRegistrantName
MeiraGTx Holdings plc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1448305
dei Entity Address Address Line1
EntityAddressAddressLine1
450 East 29th Street
dei Entity Address Address Line2
EntityAddressAddressLine2
14th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10016
dei City Area Code
CityAreaCode
646
dei Local Phone Number
LocalPhoneNumber
860-7985
dei Security12b Title
Security12bTitle
Ordinary Shares,$0.00003881 par value per share
dei Trading Symbol
TradingSymbol
MGTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
64898918
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99974000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129566000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1628000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10138000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4955000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5625000
CY2024Q2 us-gaap Income Tax Receivable
IncomeTaxReceivable
3557000
CY2023Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
13277000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
660000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1016000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
110774000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
159622000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
108844000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
115896000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
969000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1118000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1051000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1083000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1139000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1917000
CY2024Q2 us-gaap Equity Method Investments
EquityMethodInvestments
6766000
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
6766000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13823000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15910000
CY2024Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
23285000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
24432000
CY2024Q2 us-gaap Assets
Assets
266651000
CY2023Q4 us-gaap Assets
Assets
326744000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
21398000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16042000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16928000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42639000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4212000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4193000
CY2024Q2 us-gaap Deferred Income Current
DeferredIncomeCurrent
3498000
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
2926000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
970000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1278000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
47006000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
67078000
CY2024Q2 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
53763000
CY2023Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
34017000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10688000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12952000
CY2024Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2490000
CY2023Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2401000
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
72665000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
72119000
CY2024Q2 us-gaap Liabilities
Liabilities
186612000
CY2023Q4 us-gaap Liabilities
Liabilities
188567000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00003881
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00003881
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1288327750
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1288327750
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64684187
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63601015
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
706943000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
693841000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3614000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1435000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-623293000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-554231000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
80039000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
138177000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
266651000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
326744000
CY2024Q2 mgtx Service Revenue From Related Parties
ServiceRevenueFromRelatedParties
282000
mgtx Service Revenue From Related Parties
ServiceRevenueFromRelatedParties
979000
CY2023Q2 mgtx License Revenue From Related Parties
LicenseRevenueFromRelatedParties
3540000
mgtx License Revenue From Related Parties
LicenseRevenueFromRelatedParties
6874000
CY2024Q2 us-gaap Revenues
Revenues
282000
CY2023Q2 us-gaap Revenues
Revenues
3540000
us-gaap Revenues
Revenues
979000
us-gaap Revenues
Revenues
6874000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11257000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12388000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24404000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25160000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34934000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19937000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69256000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42259000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
46191000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
32325000
us-gaap Operating Expenses
OperatingExpenses
93660000
us-gaap Operating Expenses
OperatingExpenses
67419000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-45909000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-28785000
us-gaap Operating Income Loss
OperatingIncomeLoss
-92681000
us-gaap Operating Income Loss
OperatingIncomeLoss
-60545000
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-284000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1905000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-819000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
5762000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
827000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
655000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1924000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1200000
CY2024Q2 us-gaap Interest Expense
InterestExpense
3254000
CY2023Q2 us-gaap Interest Expense
InterestExpense
3355000
us-gaap Interest Expense
InterestExpense
6504000
us-gaap Interest Expense
InterestExpense
6415000
mgtx Gain Loss On Sale Of Nonfinancial Assets
GainLossOnSaleOfNonfinancialAssets
29018000
CY2023Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-1000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
53000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-48620000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29581000
us-gaap Net Income Loss
NetIncomeLoss
-69062000
us-gaap Net Income Loss
NetIncomeLoss
-59945000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-488000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2541000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2179000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4894000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49108000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32122000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71241000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64839000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48620000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29581000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-69062000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-59945000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.15
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64376396
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55349534
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64221145
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52012382
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
138177000
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4739000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1586000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
635000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1691000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-20442000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
121734000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5810000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1612000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
9000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-488000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-48620000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
80039000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117738000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5201000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2353000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30364000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
90222000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7271000
CY2023Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
61950000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4003000
CY2023Q2 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
209000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2541000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29581000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
123527000
us-gaap Profit Loss
ProfitLoss
-69062000
us-gaap Profit Loss
ProfitLoss
-59945000
us-gaap Share Based Compensation
ShareBasedCompensation
12770000
us-gaap Share Based Compensation
ShareBasedCompensation
13703000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-819000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
5762000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6497000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6339000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-100000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-104000
us-gaap Disposal Group Not Discontinued Operation Loss Gain On Write Down
DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
434000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
97000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
89000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
546000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
538000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
53000
mgtx Gain Loss On Sale Of Nonfinancial Assets
GainLossOnSaleOfNonfinancialAssets
29018000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-7764000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
10552000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-654000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-198000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-9586000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-905000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-196000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-632000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
15000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5670000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
13072000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-24928000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-17234000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
20537000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6874000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56197000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66404000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3007000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13580000
mgtx Proceeds From Gain On Sale Of Nonfinancial Assets
ProceedsFromGainOnSaleOfNonfinancialAssets
29018000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26011000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13580000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2221000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1231000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3198000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
61950000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
644000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4003000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
333000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56716000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-29853000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-23268000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
525000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130649000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115516000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
101025000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92773000
us-gaap Asset Acquisition Consideration Transferred Contingent Consideration
AssetAcquisitionConsiderationTransferredContingentConsideration
1181000
us-gaap Asset Acquisition Consideration Transferred Contingent Consideration
AssetAcquisitionConsiderationTransferredContingentConsideration
2385000
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
209000
us-gaap Interest Paid Net
InterestPaidNet
5891000
us-gaap Interest Paid Net
InterestPaidNet
6989000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-623300000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56200000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
101000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these condensed consolidated financial statements, management used significant estimates in the following areas, among others: collaboration revenue, fair value of nonfinancial assets, stand-alone selling price and material rights in connection with the Asset Purchase and Supply Agreements, the accounting for research and development costs, share-based compensation, leases, asset retirement obligations, fair value of financial instruments and tax incentive receivable.</p>
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99974000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129566000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1051000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1083000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
101025000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130649000
CY2023Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2401000
CY2022Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2179000
mgtx Asset Retirement Obligations Amortization Of Interest
AssetRetirementObligationsAmortizationOfInterest
97000
mgtx Asset Retirement Obligations Amortization Of Interest
AssetRetirementObligationsAmortizationOfInterest
89000
us-gaap Asset Retirement Obligation Foreign Currency Translation Gain Loss
AssetRetirementObligationForeignCurrencyTranslationGainLoss
-8000
us-gaap Asset Retirement Obligation Foreign Currency Translation Gain Loss
AssetRetirementObligationForeignCurrencyTranslationGainLoss
33000
CY2024Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2490000
CY2023Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2301000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13681228
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11808174
CY2024Q2 us-gaap Noncurrent Assets
NoncurrentAssets
146921000
CY2023Q4 us-gaap Noncurrent Assets
NoncurrentAssets
157356000
CY2024Q2 us-gaap Equity Method Investment Quoted Market Value
EquityMethodInvestmentQuotedMarketValue
6766000
CY2024Q2 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
6665000
CY2024Q2 mgtx Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
5529000
CY2023Q4 mgtx Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
8713000
CY2024Q2 mgtx Accrued Research And Development
AccruedResearchAndDevelopment
3736000
CY2023Q4 mgtx Accrued Research And Development
AccruedResearchAndDevelopment
5834000
CY2024Q2 mgtx Accrued Liabilities Accrued Manufacturing Costs Expense
AccruedLiabilitiesAccruedManufacturingCostsExpense
2122000
CY2023Q4 mgtx Accrued Liabilities Accrued Manufacturing Costs Expense
AccruedLiabilitiesAccruedManufacturingCostsExpense
2634000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1947000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6499000
CY2024Q2 mgtx Accrued Liabilities Accrued Compensation And Benefits
AccruedLiabilitiesAccruedCompensationAndBenefits
1491000
CY2023Q4 mgtx Accrued Liabilities Accrued Compensation And Benefits
AccruedLiabilitiesAccruedCompensationAndBenefits
12129000
CY2024Q2 mgtx Accrued Consulting Expenses
AccruedConsultingExpenses
1015000
CY2023Q4 mgtx Accrued Consulting Expenses
AccruedConsultingExpenses
2104000
CY2024Q2 mgtx Accrued Expenses Incurred In Connection With Fixed Assets
AccruedExpensesIncurredInConnectionWithFixedAssets
704000
CY2023Q4 mgtx Accrued Expenses Incurred In Connection With Fixed Assets
AccruedExpensesIncurredInConnectionWithFixedAssets
1472000
CY2024Q2 mgtx Accrued Expenses Incurred In Connection With Rent And Facility Costs
AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts
248000
CY2023Q4 mgtx Accrued Expenses Incurred In Connection With Rent And Facility Costs
AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts
142000
CY2023Q4 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
2936000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
136000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
176000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16928000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42639000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8226707
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.96
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
365100
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
254429
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.24
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8337378
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.58
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y11M23D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6468590
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M25D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8336478
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.58
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y11M23D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
540
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
540
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3200000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3500000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5810000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7271000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12770000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13703000
CY2024Q2 mgtx Modifications To Share Based Compensation
ModificationsToShareBasedCompensation
0
mgtx Modifications To Share Based Compensation
ModificationsToShareBasedCompensation
0
mgtx Excess Tax Benefit From Share Based Compensation Operating Activities1
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
mgtx Gain Loss On Sale Of Nonfinancial Assets
GainLossOnSaleOfNonfinancialAssets
29000000.0
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2700000
mgtx Operating Lease Number New Leases Recognized
OperatingLeaseNumberNewLeasesRecognized
0
CY2024Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
281000
CY2023Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
282000
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
281000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
282000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1437000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1370000
CY2024Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
41000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
39000
CY2024Q2 us-gaap Lease Cost
LeaseCost
1759000
CY2023Q2 us-gaap Lease Cost
LeaseCost
1691000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
560000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
563000
us-gaap Variable Lease Cost
VariableLeaseCost
560000
us-gaap Variable Lease Cost
VariableLeaseCost
563000
us-gaap Operating Lease Cost
OperatingLeaseCost
2872000
us-gaap Operating Lease Cost
OperatingLeaseCost
2731000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
87000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
78000
us-gaap Lease Cost
LeaseCost
3519000
us-gaap Lease Cost
LeaseCost
3372000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13823000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15910000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
14900000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
17145000
CY2024Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
23285000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
24432000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2024Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P174Y4M24D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P174Y9M18D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.088
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.088
CY2024Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.080
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.080
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1432000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1442000
us-gaap Operating Lease Payments
OperatingLeasePayments
2851000
us-gaap Operating Lease Payments
OperatingLeasePayments
2826000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2682000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5493000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5580000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1611000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1321000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
692000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17379000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2479000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
14900000
CY2024Q2 mgtx Number Of New Material Commitments
NumberOfNewMaterialCommitments
0

Files In Submission

Name View Source Status
0001558370-24-011788-index-headers.html Edgar Link pending
0001558370-24-011788-index.html Edgar Link pending
0001558370-24-011788.txt Edgar Link pending
0001558370-24-011788-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mgtx-20240630.xsd Edgar Link pending
mgtx-20240630x10q.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mgtx-20240630xex10d1.htm Edgar Link pending
mgtx-20240630xex31d1.htm Edgar Link pending
mgtx-20240630xex31d2.htm Edgar Link pending
mgtx-20240630xex32d1.htm Edgar Link pending
mgtx-20240630xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
mgtx-20240630_cal.xml Edgar Link unprocessable
mgtx-20240630_def.xml Edgar Link unprocessable
mgtx-20240630_lab.xml Edgar Link unprocessable
mgtx-20240630_pre.xml Edgar Link unprocessable
mgtx-20240630x10q_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending